Abstract: PO0542
One-Year Follow-Up of Maintenance Hemodialysis (HD) Patients Who Switched Phosphate Binder (PB) Prescription from Ferric Citrate (FC) to Sucroferric Oxyhydroxide (SO)
Session Information
- Bone and Mineral Metabolism: Clinical
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Bone and Mineral Metabolism
- 402 Bone and Mineral Metabolism: Clinical
Authors
- Ficociello, Linda, Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
- Zhou, Meijiao, Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
- Parameswaran, Vidhya, Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
- Mullon, Claudy, Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
- Anger, Michael S., Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
Background
A new class of iron based PBs have been prescribed to HD patients for hyperphosphatemia management. This one-year real-world data analysis in a contemporary cohort of HD patient who switched from FC to SO as part of routine care investigates changes in serum phosphorus (sP) and pill burden.
Methods
Adult Fresenius Kidney Care HD patients included in the analysis were first prescribed SO monotherapy between 5/2018- 5/2019 and were on FC for 3 months (baseline; BL) prior to SO therapy. The one year SO therapy was divided into four consecutive 91-day intervals (Q1-Q4). Changes in lab measurements and PB pill burden were compared between BL and Q1-Q4, using mixed-effects linear regression and Cochran's Q test.
Results
Patients (n=115) were on average 55.5 (12.6) years old with 52.8 (46.4) months HD vintage, 38% female, 54% had diabetes and 20% had CHF. There were consistent improvements in pts achieving sP ≤ 5.5 mg/dL (from 20% at BL to 35.7%- 44.3% with SO; p<.0001) and in patients achieving sP≤ 4.5 mg/dL (from 6.1% at BL to 8.7%- 16.5% with SO; p=0.02). Pts were prescribed 6.7 pills/day at BL and 4.7-5.2 pills/day with SO. SO conversion was associated with decreases in mean iPTH (620 pg/mL at BL, 496 pg/mL at Q4; p<.0001) and serum calcium (9.18 mg/dL at BL, 8.93 mg/dL at Q4; p<.0001).
Conclusion
Maintenance HD pts switched PB prescription from ferric citrate to sucroferric oxyhydroxide experienced significant increases in % patients achieving in-range sP (+111% for sP ≤5.5mg/dL and +144% for sP ≤4.5mg/dL) with a lower pill burden.
Funding
- Commercial Support –